Skip to content

Released Mar 31, 2022, before the open

10-K filed Mar 31, 2022, 90 days after period end · 0001558370-22-004823

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$8.55Mderived−56.1% vs Q4 2020−29.1% vs Q3 2021
Net Income-$6.67MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,706,000N/M
Operating Cash Flowderived-$5,087,000N/M
Free Cash Flowderived-$5,535,000N/M
Margins · derived
Operating margin-66.7%−81.3 pt vs Q4 2020
Net margin-78.0%−80.0 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019Q4 2018
Revenue$8.55M$19.50M$17.76M$27.02M
Net Income-$6.67M$397.00K$291.00K-$5.43M
EPS Diluted——$0.02-$0.40

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR